Cellular Therapy with Engineered T Cells, Efficacy and Side Effects
- PMID: 32091787
- Bookshelf ID: NBK553971
- DOI: 10.1007/978-3-030-02278-5_60
Cellular Therapy with Engineered T Cells, Efficacy and Side Effects
Excerpt
The cellular basis of cancer immune surveillance, already hypothesized in ancient times, was only demonstrated with the advent of HSCT. Indeed, the discovery of the nature of GVHD and its antileukemic effects (Weiden et al.
Copyright 2019, EBMT and the Author(s).
Sections
References
-
- Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997;276:1719–24. - PubMed
-
- Casucci M, Nicolis di Robilant B, Falcone L, et al. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood. 2013;122:3461–72. - PubMed
-
- Ciceri F, Bonini C, Stanghellini MT, et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I–II study. Lancet Oncol. 2009;10:489–500. - PubMed
Publication types
LinkOut - more resources
Full Text Sources